Ipsen Group
Ipsen is a global biopharmaceutical group dedicated to improving lives through innovative medicines in Oncology, Neuroscience and Rare Diseases. We also have a well-established and successful Consumer Healthcare business. We are committed to discovering new solutions for targeting debilitating diseases and improving the quality of life for patients.
Ipsen group
We have 90 years of heritage as a family-owned company and a publicly traded business.
We sell more than 20 drugs in 115 countries and have a direct commercial presence in over 30 countries worldwide.
We focus on Specialty Care with businesses in Oncology, Neuroscience and Rare Diseases, as well as a Consumer Healthcare business.
We have over 5,800 employees worldwide, who are based at our many sites, including 8 R&D sites and 8 industrial sites.
We are proud that 15.1% of our sales are reinvested in R&D, some €388.8m in 2019.
In 2019, total sales exceeded €2.5bn and we are seeing double digit growth in Europe and growth of almost 20% in North America.
We are one of the world’s top 15 biopharmaceutical companies in terms of oncology sales.
Therapeutic areas
Ipsen is a global biopharmaceutical group dedicated to improving lives through innovative medicines in Oncology, Neuroscience and Rare Diseases. We also have a well-established and successful Consumer Healthcare business. We are committed to discovering new solutions for targeting debilitating diseases and improving the quality of life for patients.
Executive management
Richard
Paulson*
Executive Vice-President & CEO of Ipsen North America
Richard Paulson was appointed Executive Vice-President and Chief Executive Officer of Ipsen North America, effective 5th February 2018.
He is responsible for driving continued growth in both the US and Canadian markets across key therapeutics areas of oncology, neurology and rare diseases.
During a 10-year career at Amgen, Richard Paulson held a number of positions in the company, including General Manager, Central and Eastern Europe, and subsequently General Manager Germany, before assuming leadership positions in Amgen’s Oncology Business Unit. Prior to joining Amgen, he held international positions in general management, marketing and market access with Pfizer. He also served in a number of sales and marketing roles with increasing seniority for GlaxoWellcome in Canada.
Richard earned his undergraduate degree in Commerce from the University of Saskatchewan, Canada, and his MBA from the University of Toronto, Canada.
Harout
Semerjian*
Executive Vice President, Chief Commercial Officer
Harout Semerjian was appointed Executive Vice-President & President , Specialty Care International & Global Franchises in February 2017, and as of March 2018 was appointed Executive Vice-President & Chief Commercial Officer.
Harout has more than 23 years of pharmaceutical experience, including the last 17 years at Novartis focused on oncology and specialty care. He took on leadership roles with increasing responsibility across the U.S., Canada, Europe, Middle East & North Africa in addition to headquarter-based roles. His last role was Senior Vice President and Global Launch Head of ribociclib. Prior to that, he was Vice President and U.S. Hematology Franchise Head based in New Jersey.
He holds dual MBA degrees from Cornell University, New York and from Queen’s University, Canada. He also holds a Bachelor Degree of Science in Biology from the Lebanese American University.
Dominique
Bery*
Executive Vice President, Strategy & Transformation
Executive vice president, strategy & transformation
Dominique joined Ipsen in April 2017.
Dominique spent the previous 18 years with McKinsey & Company, where she was elected Partner in 2010. Dominique co-led the Pharmaceuticals and Medical Products Practice in Europe and served multiple pharmaceutical and biotech companies. She also worked with diagnostics companies, hospitals, payors, ministries of health, patient associations, and public health organizations, gaining extensive experience in the healthcare industry.
Located in Paris and Washington, Dominique led many company-wide transformation projects across Europe, US and Africa, working hand in hand with management and their teams. She supported clients to set their strategic priorities at corporate, business unit, and therapeutic area level, and she worked with a number of brand teams to accelerate brand performance. She brings a truly cross-functional perspective, having worked closely with most functions in pharmaceutical companies. In parallel, she initiated the creation of a community of women executives in France, focused on developing the capabilities of women executives on key business topics such as innovation, leadership in transformation, business model disruption.
Dominique is a graduate from ESSEC and holds a Masters in Business Administration from Harvard Business School.
François
Garnier*
Executive Vice President, General Counsel
François Garnier was appointed Executive Vice-President, General Counsel in December 2014.
François began his career in 1989 at Servier S.A. as International Contracts Manager, and remained with the company until September 1995. He then moved to Rhône Poulenc Rorer S.A. to take up the position of Counsel for Corporate Transactions. In 1996 he moved to the United States as Associate Counsel, before being appointed Chief Counsel for France in 1999. François continued his career as Chief Counsel at Aventis Animal Nutrition until 2001, when he joined the Pharmacia Group as Chief Counsel for Europe.
Francois joined Pfizer France in 2003, as Vice-President, General Counsel before moving on to become Chief Counsel for Pfizer’s operations in Europe from 2009 to 2014. He was International Chief Counsel (ex-US) for Pfizer Inc. from January 2014.
A student from the IEP in Paris, Francois graduated from the University of Panthéon-Assas prior to working in the legal departments of a number of pharmaceutical groups.
Benoît
Hennion*
Executive Vice President, CHC
Benoît Hennion has been Executive Vice-President, Consumer Healthcare since March 2017.
Benoît joined Ipsen in 2006 within the Corporate Strategic Planning team. In 2009, he became Business Unit Head, and subsequently in 2011, General Manager France leading both Specialty Care and Consumer Healthcare. In 2014, Benoît was appointed Vice President Asia-Pacific Specialty Care, based in Seoul, Korea for three years. Benoît gained his MBA degree at ESSEC (Paris, France). Before joining Ipsen, he started his career at Société Générale in the Czech Republic and then served for six years in the Paris office of Roland Berger Strategy Consultants.
Dominique
Laymand*
Executive Vice President Ethics and Social Responsibility Officer
Dominique Laymand was appointed Executive Vice-President, Chief Ethics and Compliance Officer in October 2017.
Dominique Laymand joined Ipsen in 2015 as Senior Vice-President, Chief Ethics and Compliance Officer.
Dominique is in charge of Ethics & Compliance strategy for the Ipsen Group, the deployment of the Global Ethics & Compliance program and the organization of this department. The Global Ethics & Compliance program is based on an integrated approach to prevention and management of operational risks, as well as on strong principles of integrity and ethics in the conduct of business.
Previously Dominique served as Vice-President Ethics & Compliance at Bristol Myers Squibb, setting up and managing the Ethics & Compliance Europe, Middle East, Africa, Turkey and Russia program.
Dominique also chairs the committee of compliance at the European Federation of Pharmaceutical Industries and Associations (EFPIA) and also at the French Association of Pharmaceutical Industries (Leem).
Dominique is the president of ETHICS, an association which includes international professionals in Ethics and Compliance working in the healthcare sector.
Ivana Magovčević-Liebisch*
Executive Vice President, Chief Business Officer
Ivana Magovčević-Liebisch Ph.D, J.D was appointed Executive Vice President, Chief Business Officer in March 2018. She is in charge of Business Development, External Innovation and Strategic Alliances.
Ivana joins Ipsen from Axcella Health Inc., where she served as Executive Vice President, Chief Strategy and Corporate Development Officer. Prior to joining Axcella, Ivana was Senior Vice President and Head of Global Business Development at Teva Pharmaceutical Industries Ltd (2013-17), where she led and executed multiple business development transactions ranging from licensing to acquisition of drug candidates, commercial products and companies for the global specialty drug business. She previously worked at Dyax Corp (2001-13) in management roles of increasing scope and responsibility, including Executive Vice President and Chief Operating Officer. Ivana began her biopharma career at Transkaryotic Therapies, Inc (1998-2001), where she was Director of Intellectual Property and Patent Counsel.
Ivana serves as a member of the Board of Directors of Applied Genetic Technologies Corporation (AGTC), is also a member of the Board of Directors for Alivio Therapeutics, and was most recently appointed to the Board of Directors of Aeglea BioTherapeutics. Ivana is Trustee of Suffolk University, and an overseer of the Boston Ballet, Boston Museum of Science and Beth Israel Deaconess Medical Center.
Ivana holds a Ph.D. in Genetics from Harvard University and received her J.D. in High Technology law from Suffolk University Law School. She graduated from Wheaton College with a B.A. in Biology and Chemistry. In 2008, Ivana was the winner of the Women Entrepreneurs in Science and Technology Leadership Award.
Christian
Marcoux
Senior Vice-President, Global Communications
Christian Marcoux was appointed Senior Vice-President, Global Communications in December 2018. Christian is a seasoned communications expert with more than 20 years of experience in managing large multi-disciplinary communications teams.
His background is rich and varied, from financial communications, to public relations, to internal and digital communications.
Christian began his career working as Manager, Brand Communications for Merck and Pfizer Canada. In 2010, Christian was appointed Associated Vice-President, Global Internal Communications at Sanofi, where he also acted as Chief Communication Officer on the Genzyme and Merial acquisitions. Christian went back to Canada in 2013 where he opened the Montreal office of Weber Shandwick, while overseeing its national health practice.
Christian holds a Graduate Degree in Organizational Communications and a Bachelor’s Degree in English Literature from the University of Montreal, Quebec, where he also worked as Lecturer in the Communications Department.
Régis
Mulot*
Executive VP, Chief Human Resources Officer
Régis Mulot joined Ipsen Pharma, in March 2018, as Executive Vice President, Chief Human Resources Officer
Régis Mulot joins Ipsen from Staples Inc., the global specialty retail and e-commerce company, where he served as Executive Vice-President, Chief Human Resources Officer, leading a global team of over 600 professionals. Prior to his career with Staples (2009-18), Mr Mulot held HR leadership positions with Levi Strauss & Co (2002-08) and the technology start-up Broadnet Europe (2000-02), following earlier roles at GTECH Corporation (1994-2000), International Post Corporation (1991-94) and Chronopost SA (1989-91).
Mr Mulot served on the Board of Trustees, Simmons College (Boston M.A.); is Past Chairman of the Business Advisory Committee of the Simmons School of Management 2014-2017; Founder and former chair of the French-American HR Forum since 2016-2018. He has been Co-chair of the Boston CHRO (Chief Human Resources Officers) Leadership summit between 2014 and 2018, and is a Gartner CHRO Leadership Board member since 2017.
Mr Mulot holds a DESS Entreprises Publiques (Master in Public Administration) from Paris XI-Sud in partnership with Paris IX-Dauphine and Institut International d’Administration Publique (IIAP). He also holds a Maîtrise Droit Public (Bachelor of Law) from Paris II–Panthéon-Assas, and is a Beta Gamma Sigma honoree from the Simmons College Chapter.
Aidan
Murphy*
Executive Vice-President, Technical Operations
Dr Aidan Murphy was appointed Executive Vice-President, Technical Operations, effective 1st January 2018. Dr Murphy has more than 25 years experience in the pharmaceutical and biotechnology industry, and since joining Ipsen in 2006 has held a number of manufacturing leadership roles in many countries.
Since 2014 Dr Murphy has held the position of Senior Vice President Biologics Development and Manufacturing at Ipsen. Also during his tenure at Ipsen, he has led the manufacturing sites of Tianjin (China), Dublin (Ireland), and Wrexham (UK) and occupied global roles as SVP CMC (Chemistry, Manufacturing, and Controls) Development & Engineering and Head of Specialty Care Manufacturing. He holds a PhD in organic chemistry from Trinity College, Dublin.
Howard
Mayer*, M.D.
Executive Vice President and Head of Research and Development.
Howard Mayer, M.D., is Executive Vice President and Head of Research and Development at Ipsen Pharmaceuticals. Dr. Mayer joined Ipsen in 2019 from Shire, where he was Chief Medical Officer, responsible for the hematology, immunology, oncology, genetic diseases, GI/metabolic, neuroscience and ophthalmology therapeutic areas.
Previously, Dr. Mayer served as Chief Medical Officer at EMD Serono, a division of Merck KGaA. Prior to that, he held a variety of global roles at Pfizer, including Head, Clinical Development and Medical Affairs for Virology/Infectious Diseases. Prior to joining Pfizer, he served as Director of Clinical Research at Bristol-Myers Squibb.
Dr. Mayer obtained his BA from the University of Pennsylvania and his M.D. from Albert Einstein College of Medicine, which was followed by an internship and residency at Mount Sinai Hospital and an Infectious Diseases fellowship at Harvard Medical School. He currently serves on the board of directors for Genocea Biosciences and Entasis Therapeutics, and on the board of Autism Speaks in New England. He was honored by PharmaVoice as one of the 100 Most Inspiring People in the Life Sciences Industry in both 2011 and 2017.
Aymeric
le Chatelier*
Ipsen’s Chief Executive Officer
Aymeric Le Chatelier was appointed Chief Executive Officer on January 1st 2020, and retains the function of Executive Vice-President, Group Chief Financial Officer, which he has held since 2014.
Aymeric, a graduate from HEC Business School, started his career at Arthur Andersen. He successively executed several roles in finance in France and the United States at Veolia. He then joined Arjowiggins, a leading manufacturer of creative and technical paper, as Group Chief Financial Officer. He was subsequently appointed Financial Director of Enedis and member of the Management Board.
Board of Directors
The Board of Directors ensures that the company’s shareholders and the general public are provided with accurate information. It ensures that the company has reliable procedures for identifying, measuring and monitoring its commitments and risks, as well as adequate financial and operational internal controls.
Board Committees
The Board of Directors has set up six permanent committees and has defined both the composition and powers of these committees.
Ipsen history
April 2019: Acquisition of Clementia Pharmaceuticals
Read more
Paris, 18 April 2019 – Ipsen and Clementia Pharmaceuticals announced the closing of Ipsen’s acquisition of Clementia following approval of the arrangement by Clementia shareholders and the Quebec Superior Court.
Clementia’s key late-stage clinical asset palovarotene is an investigational retinoic acid receptor gamma (RARγ) selective agonist, for the treatment of two rare bone disorders, fibrodysplasia ossificans progressiva (FOP) and multiple osteochondromas (MO), and other diseases.
Early 2017: Acquisition of oncology assets from Merrimack pharmaceuticals
Read more
2017
Paris (France), 9 January 2017 – Ipsen announced that it has entered into a definitive agreement to acquire global oncology assets from Merrimack Pharmaceuticals, including its key marketed product ONIVYDE® (irinotecan liposome injection) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy, in combination with fluorouracil and leucovorin. Under the terms of the agreement, Ipsen will gain exclusive commercialization rights for the current and potential future ONIVYDE indications in the U.S., as well as the current licensing agreements with Shire for commercialization rights ex-U.S. and PharmaEngine for Taiwan. The transaction also includes Merrimack’s commercial and manufacturing infrastructure, and generic doxorubicin HCl liposome injection. The transaction represents a unique opportunity and a strong strategic fit for Ipsen. ONIVYDE is a clinically differentiated and FDA-approved product for patients with high unmet medical needs.2017
March 2016: Ipsen’s oncology pipeline was reinforced by a licensing deal with Exelixis
Read more
2016
Exelixis, Inc. and Ipsen jointly announced an exclusive licensing agreement for the commercialization and further development of cabozantinib, Exelixis’ lead oncology drug. Under the agreement, Ipsen will have exclusive commercialization rights for current and potential future cabozantinib indications outside the United States, Canada and Japan, including COMETRIQ®, which is currently approved in the European Union (EU) for the treatment of adult patients with progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC). The companies have agreed to collaborate on the development of cabozantinib for current and potential future indications. Exelixis will maintain exclusive commercial rights for cabozantinib in the United States and Canada, and continue its discussions to partner commercial rights in Japan.
April: Ipsen opened its new peptide-driven R&D center in Cambridge (USA).
Read more
2015
- April 1st: Ipsen opened its new peptide-driven R&D center in Cambridge (USA).
- May, 19: Ipsen strengthened its oncology expertise with the acquisition of OctreoPharm Sciences, a German company developing innovative radiopharmaceutical products for the diagnosis and treatment of neuroendocrine tumors.
- July 18: The Food and Drug Administration approved botulinum toxin DYSPORT® as a treatment for adult upper-limb spasticity in the US.
- August,3: Ipsen’s partner Lexicon Pharmaceuticals announced positive results from a late-stage trial that evaluated the efficacy and safety of telotristat etiprate for carcinoid syndrome patients with advanced neuroendocrine tumors whose symptoms are inadequately controlled by somatostatin analogs.
- Ipsen strengthened its primary care portfolio with the launch in France of strawberry-flavored SMECTA® and SMECTALIA® stick for adults, an OTC ready-to-use formulation of SMECTA®.
Ipsen’s SOMATULINE® DEPOT® gets FDA approval
Read more
2014
- SOMATULINE® DEPOT® (lanreotide) Injection 120 mg (referred to as SOMATULINE®) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Pancreatic and gastrointestinal neuroendocrine tumors are rare cancers. There are an estimated 112,000 individuals currently living with pancreatic and gastrointestinal neuroendocrine tumors in the U.S
- Ipsen announces FDA acceptance of filing for DYSPORT® in the treatment of upper limb spasticity in adult patients
- Ipsen and the Salk Institute renew their agreement for discovery research in medical sciences. The 2011-2014 collaboration enabled significant steps forward in the understanding of basic biological mechanisms. Ipsen to support innovative Salk investigations into biology for another three years
- The Fondation Ipsen celebrates its 30th anniversary with a prestigious conference on the perspectives of cancer research, “Biology viewed through the prism of cancer”, attended by 8 Nobel Prize laureates and the greatest scientists in biomedical research.
Teijin Pharma Limited and Ipsen launched SOMATULINE® in Japan
Read more
2013
- Teijin Pharma Limited and Ipsen launch of SOMATULINE® 60/90/120 mg for subcutaneous injection in Japan for the treatment of acromegaly and pituitary gigantism.
- Ipsen and Inspirations Biopharmaceuticals announce closing of the sale of OBI-1 and Milford facility to Baxter International
- Health Canada has granted amarketing authorization for DYSPORT® for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients under 65 years of age. Medicis Aesthetics Canada, a division of Valeant Pharmaceuticals, will market DYSPORT® for use in aesthetic medicine in Canada.
- Christel Bories joins Ipsen as Deputy CEO. Working alongside Marc de Garidel, Chairman and CEO, Christel Bories is responsible for accelerating the execution of the Group’s strategy.
- Ipsen strengthens its neurology R&D capabilities with the acquisition of Syntaxin, a leader in recombinant botulinum toxin technology.
Ipsen enters into a research partnership with Oncodesign to develop new therapeutic agents
Read more
2012
- Ipsen and Active Biotech present encouraging results from the tasquinimod Phase II study in chemotherapy-naïve metastatic castrate resistant prostate cancer and initiate a new phase II, proof-of-concept clinical trial to evaluate the safety and efficacy of tasquinimod in other cancer indications.
- SOMATULINE® receives marketing authorization in Japan for the treatment of acromegaly and pituitary gigantism and becomes Ipsen’s first drug available worldwide.
- Inspiration Biopharmaceuticals, Inc., Ipsen’s partner, initiates a voluntary reorganization plan of its activities under the Chapter 11 of US Bankruptcy Code.
Ipsen announces a new development strategy based on three pillars
Read more
2011
Ipsen announces a new comelopment strategy based on three pillars:
- Focus resources and investments on specialty care
- Invest to grow through the comelopment of new compounds and product life-cycle management programs
- Leverage the full potential of the Group’s geographical footprint
Ipsen and the Salk Institute renew the “Ipsen Life Sciences Program” for a further three years.
Syntaxin and Ipsen enter into a strategic agreement to comelop novel botulinum-toxin therapeutics.
Ipsen strengthens its business in urology-oncology with the acquisition of the rights to HEAVY® (a drug aimed at improving bladder cancer detection) and the establishment of two significant partnerships with: Active Biotech for the co-comelopment and commercialization of tasquinimod (a molecule for the treatment of metastatic and castration-resistant prostate cancers), and Institut Gustave Roussy in the area of medical oncology to leverage the combined expertise of their respective R&D teams.
Ipsen and Inspiration Biopharmaceuticals Inc. enter into a partnership
Read more
2010
- Ipsen and Inspiration Biopharmaceuticals Inc. enter into a partnership to create a hemophilia franchise.
- Ipsen increases its presence in oncology and endocrinology in South-East Asia through a commercialization agreement with Invida.
- Ipsen grants Menarini exclusive license rights to ADENURIC® (for the treatment of chronic hyperuricemia in gout) in 41 countries. Ipsen retains co-promotion rights in France.
- Ipsen and Rhythm Pharmaceuticals, a biotechnology company comeloping peptide therapeutics for metabolic diseases, enter into a license agreement for Ipsen’s proprietary peptide therapeutics targeting obesity, metabolic diseases, and gastrointestinal disorders.
- Ipsen grants Rhythm an exclusive worldwide license for research, comelopment, and commercialization of its melanocortin and ghrelin programs originating from Ipsen’s research.
- Marc de Garidel is appointed Chairman and Chief Executive Officer
Ipsen and Galderma receive collective green light for AZZALURE® from 15 European countries
Read more
2009
- Ipsen and Galderma receive collective green light for AZZALURE® from 15 European countries’ Health Authorities for the granting of national marketing authorizations for the treatment of glabellar lines.
- AZZALURE® receives marketing authorization in the UK, France and Germany. The FDA approves DYSPORT™ for therapeutic and aesthetic use.
- The European Medicines Agency (EMA) delivers marketing authorization for the 6-month formulation of DECAPEPTYL® in nine European countries. The product is launched in France
Ipsen initiates a partnership with the Salk Institute for Biological Studies (San Diego)
Read more
2008
- Ipsen initiates a partnership with the Salk Institute for Biological Studies (San Diego, US) aimed at improving understanding of proliferative and degenerative diseases.
- Ipsen reinforces its presence in the US with three acquisitions: Tercica Inc. in endocrinology, APOKN® in neurology and Vernalis’ US commercial operations, and all assets related to OBI-1 from Octagen in hematology.
The Group enters into a partnership with Galderma
Read more
2007
- The Group enters into a partnership with Galderma, for the comelopment, promotion and distribution of the Group’s botulinum toxin type A in aesthetic medicine indications.
- SOMATULINE® DEPOT obtains marketing authorization in the United States for the treatment of acromegaly. SOMATULINE® DEPOT is the first product stemming from Ipsen’s R&D to be approved by the FDA.
- Ipsen’s shares are admitted to the SBF 120 index in France.
Ipsen enters into an agreement with Medicis (now Valeant)
Read more
2006
- Ipsen enters into an agreement with Medicis (now Valeant) to market its botulinum toxin in aesthetic medicine indications in the US, Canada and Japan.
- Ipsen and Tercica complete worldwide strategic collaboration agreement in Endocrinology. Ipsen grants Tercica exclusive rights to market SOMATULINE® AUTOGEL® in the United States and in Canada.
- Tercica grants Ipsen exclusive rights to market INCRELEX™, a leading product in the United States for the treatment of short stature associated with severe primary IGF-1 deficiency in all territories excluding the United States, Japan, Canada, Taiwan and certain countries of the Middle East and North Africa.
Ipsen’s shares are listed on Euronext Paris.
Read more
2005
- Ipsen’s shares are listed on Euronext Paris.
- Ipsen enters into a licensing agreement with Radius through which Radius acquires the exclusive worldwide rights (excluding Japan) to develop, manufacture and distribute Ipsen’s osteoporosis proprietary molecule.
The Group opens a botulinum toxin manufacturing facility in Wrexham
Read more
2004
- The Group opens a botulinum toxin manufacturing facility in Wrexham (United Kingdom).
Ipsen and Teijin enter into an agreement to develop and market four Ipsen products
Read more
2003
- Ipsen and Teijin enter into an agreement to develop and market four Ipsen products, notably SOMATULINE® AUTOGEL®, in Japan and a Teijin product for the treatment of gout in Europe.
Ipsen launches SOMATULINE® AUTOGEL® in the UK, France followed by many other countries.
Read more
2001-2002
- Ipsen launches SOMATULINE®AUTOGEL® in the UK, France followed by many other countries, strengthening Ipsen’s competitive position. To the Group’s knowledge, SOMATULINE® AUTOGEL® is the first semi-solid formulation for injection without any excipient, since the active substance controls the sustained release.
The Group is opening a manufacturing facility in China.
Read more
2000
- The Group is opening a manufacturing facility in China. This facility will manufacture SMECTA® for the Chinese market, which is a reference treatment in the country.
Ipsen launches FORLAX®, a product used for the treatment of constipation.
Read more
1996
-
Ipsen launches FORLAX®, a product used for the treatment of constipation.
The Group launches SOMATULINE®, a sustained-release peptide...
Read more
1995
- The Group launches SOMATULINE®, its sustained-release peptide for the treatment of acromegaly and neuroendocrine tumors in France.
Ipsen acquires Speywood, the company that developed DYSPORT®
Read more
1994
- Ipsen acquires Speywood, the company that developed DYSPORT® for the treatment of movement disorders and various forms of muscular spasticity.
- This acquisition strengthens the Group’s presence in the UK and Northern Europe.
- Ipsen establishes a sales platform for its biological product and opens an office in Russia.
Ipsen begins its development in China, with the opening of a representative office...
Read more
1992
- Ipsen begins its development in China, with the opening of a representative office in Tianjin.
The Group creates La Fondation Ipsen under the aegis of the Fondation de France
Read more
1983
-
The Group creates La Fondation Ipsen under the aegis of the Fondation de France. Its mission is to foster interactions between leading scientists in the field of life sciences.
Ipsen initiates a partnership with Debiopharm....
Read more
1980
- Ipsen initiates a partnership with Debiopharm. This collaboration leads to the marketing of DECAPEPTYL® in 1986. This analogue of natural GnRH hormone (or gonadotropin) is indicated for the treatment of prostate cancer, endometriosis and infertility. DECAPEPTYL® has been a key driver of the Group’s international expansion.
The Group enters an expansion phase...
Read more
1970
- The Group enters an expansion phase with the launch of GINKOR®, TANAKAN® and SMECTA®. The Group creates Laboratoires Ipsen (Institute of Synthetic Products from Natural Extraction).
The Group opens its first research facility in Les Ulis (France).
Read more
1969
- The Group opens its first research facility in Les Ulis (France).
The Group launches Citrate de BETAïNE®
Read more
1954
- The Group launches Citrate de BETAïNE®,a product used in the symptomatic treatment of dyspepsia.
Dr. Henri Beaufour creates Laboratoires Beaufour in Dreux (France)
Read more
1929
- Dr. Henri Beaufour creates Laboratoires Beaufour in Dreux (France) to launch ROMARÉNE®, a product derived from rosemary for the treatment of digestive disorders.
Financial outlook
The Group has updated its 2022 outlook taking into account the latest developments in its current business, mainly in the palovarotene development program:
- Group net sales greater than €2.8 billion, assuming current level of exchange rates;
- Core Operating margin greater than 28.0% of net sales
The outlook has been updated assuming no approval of additional meaningful products or indications (including no contribution from palovarotene), progressive entry of additional octreotide and lanreotide generics globally from 2021 and excluding the impact of incremental investments in pipeline expansion initiatives.